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Glomerular endothelial cells (GEnC) are specialized cells with
important roles in physiological filtration and glomerular
disease. Despite their unique features, GEnC have been little
studied because of difficulty in maintaining them in cell
culture. We have addressed this problem by generation of
conditionally immortalized (ci) human GEnC using
technology with which we have previously produced ci
podocytes. Primary culture GEnC were transduced with
temperature-sensitive simian virus 40 large tumour antigen
and telomerase using retroviral vectors. Cells were selected,
cloned, and then characterized by light and electron
microscopy (EM), response to vascular endothelial growth
factor (VEGF), and tumour necrosis factor (TNF)a, expression
of endothelial markers by focused gene array,
immunofluorescence and Western blotting, and formation
and behaviour of monolayers. CiGEnC proliferated at the
permissive temperature (331C) and became growth arrested
at the non-permissive temperature (371C). CiGEnC retained
morphological features of early-passage primary culture
GEnC up to at least p41, confirming successful
immortalization. EM demonstrated fenestrations, increased in
number by VEGF. mRNA analysis confirmed expression of the
endothelial markers platelet endothelial cell adhesion
molecule 1, intercellular adhesion molecule 2, VEGF receptor
2, and von Willebrand factor, validated by
immunofluorescence and Western blotting. CiGEnC also
expressed Tie2, and TNFa upregulated E-selectin. CiGEnC
formed monolayers with barrier properties responsive to
cyclic adenosine 30,50 monophosphate (cAMP) and thrombin.
CiGEnC retain the markers and behaviour of primary culture
GEnC. They express fenestrations which are upregulated in
response to VEGF. These cells are a unique resource for
further study of GEnC and their roles in glomerular filtration,
glomerular disease, and response to glomerular injury.
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The glomerular microcirculation, unlike other capillary
circulations, is highly permeable to water and small solutes,
yet, like other capillaries, is relatively impermeable to
macromolecules. These properties are essential for filtration
function and are a result of the unique three-layer structure
of the glomerular capillary wall: the endothelium with its
glycocalyx, the glomerular basement membrane, and podo-
cytes. Much interest has recently focused on the podocyte
and particularly the slit diaphragm as a possible site of a final
barrier to macromolecular passage.1 However, models
indicate that all three layers have an important contribution
and that their combined properties are more than simply the
sum of the parts.2,3
Glomerular endothelial cells (GEnC) are highly specialized
cells, which form a continuous inner layer of glomerular
capillaries. Away from the nucleus the cytoplasm is
attenuated to 200 nm and is punctuated by numerous
fenestrae. These are circular transcellular pores, 60–80 nm
in diameter,4 which cover 20% of the endothelial surface3 and
are essential for high hydraulic conductivity. Previously, the
fenestrations were thought of as empty and therefore
providing little barrier to the passage of proteins.5 However,
new fixation techniques have allowed the demonstration of a
glomerular endothelial glycocalyx of 200–400 nm in thick-
ness, which covers fenestrae and interfenestral domains
equally.4 Although the exact nature of this GEnC glycocalyx
is yet to be defined, these observations suggest that the
contribution of GEnC to the permeability barrier to proteins
may have been underestimated.6
GEnC are also likely to be important in glomerular disease.
There is clear evidence of GEnC damage in conditions such as
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haemolytic uraemic syndrome7 and pre-eclampsia.8 Diseases
such as haemolytic uraemic syndrome, vasculitis, and anti-
glomerular basement membrane disease involve destruction
of glomerular capillaries and experimental models indicate
that recovery is dependent on GEnC angiogenesis.9–11
Systemic conditions such as diabetes, hypertension, and sepsis
are associated with microalbuminuria and, although the
mechanism of this link is not known, the generalized
endothelial dysfunction that accompanies these conditions
suggests a contribution from a GEnC lesion.12,13
In addition to their unique structure and function, GEnC
also have a particular embryological origin, arising by a
combination of vasculogenesis from mesenchymal precursors
(predominantly) and in-growth of existing vessels.14,15
Furthermore increasing evidence indicates that EnC from
different species, organs, and types of vessels have different
properties and behaviours.16–18
All these considerations indicate the importance of the
study of human GEnC to enable complete understanding of
glomerular filtration, glomerular disease, response to glo-
merular injury, and the potential for therapeutic manipula-
tions in these contexts. While certain responses are most
appropriately examined in vivo, cell culture allows careful
analysis of the behaviour of individual cell types and the
actions and interactions of particular mediators. Historically,
GEnC have been difficult to grow in culture and have
therefore been little studied. We have now addressed this
problem using conditional immortalization (ci) technology,
such as we have successfully applied previously in cultured
podocytes.19 While a number of groups have now successfully
cultured rodent or bovine GEnC,20–23 there are few reports
convincingly demonstrating isolation of human GEnC.7 In
this case GEnC were cultured from glomeruli sieved from
normal renal cortex. The technique involved partial collage-
nase digestion of the glomerulus, coating of culture plates
with extracellular matrix components, use of medium with
EnC growth factors, and purification of GEnC from
contaminating cells using an immunomagnetic bead selection
technique. Human GEnC, similarly derived from glomeruli
decapsulated by sieving, have also become available from a
commercial source and we have previously characterized
these cells in detail.24 Other described culture methods for
‘glomerular’ EnC, which begin with lysing whole cortex,25,26
result in a mixture of EnC, only some of which are
glomerular.
When successfully isolated, primary culture GEnC form a
monolayer of polygonal cells, which express typical EnC-
specific markers including von Willebrand factor (vWF),
platelet endothelial cell adhesion molecule 1 (PECAM1,
CD31), and vascular endothelial (VE)-cadherin (CD144),
and growth factor receptors Tie2 and vascular endothelial
growth factor receptor 2 (VEGFR2).7,24 These cells, like other
EnC, respond to inflammatory mediators, including tumour
necrosis factor (TNF)a, by upregulation of the adhesion
molecule E-selectin (CD62E), and they form monolayers in
culture whose permeability properties are responsive to cyclic
adenosine 30,50 monophosphate (cAMP) and thrombin.
Human primary culture GEnC express some fenestrations
in culture,7 while bovine GEnC do not express fenestrations
in static culture but can be induced by shear stress.27
The usefulness of primary culture human GEnC for tissue
culture studies is limited by early onset of senescence. Here
we describe the ci of human GEnC. We have used a technique
restoring functional telomerase activity and introducing the
simian virus 40 large tumour antigen (SV40LT), since it has
been shown that human EnC require both these elements for
successful immortalization.28 A temperature-sensitive (ts)
SV40LT construct was used to allow ci, that is, enhanced
proliferation at a permissive temperature, while the SV40LT
element can be ‘switched off ’ by transfer to a non-permissive
temperature. At this temperature, cells take on a mature
phenotype not seen in cells constitutively expressing SV40LT.
This approach has been used successfully in alveolar bone
marrow cells,29 breast microvascular EnC and fibroblasts,28
and in podocytes in our laboratory.19
RESULTS
Cell culture and phase-contrast microscopy
Clones of ciGEnC successfully transduced with both SV40LT
and the essential catalytic subunit of human telomerase
(hTERT) were antibiotic-resistant and proliferated at 331C
with growth arrest occurring on transfer to 371C. CiGEnC at
both 331C and 371C retained features of early-passage
primary culture GEnC, including small size, homogeneity,
and formation of ‘cobblestone’ monolayers up to at least
passage 41 (Figure 1), while primary culture GEnC became
senescent by passage 8 (not shown). CiGEnC at 371C were
used in experiments after at least 5 days at the non-
permissive temperature.
Scanning electron microscopy
Scanning electron microscopy of ciGEnC monolayers de-
monstrated the presence of cytoplasmic pores of 50–400 nm
37°C33°C
Passage
13
Passage
41
Figure 1 | Phase-contrast microscopy showing ciGEnC at early
(13) and late (41) passage and at the permissive (331C) and non-
permissive (371C) temperatures. CiGEnC maintain morphological
appearances of primary culture GEnC (not shown) at late passage.
Original magnification  100.
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in diameter which were taken to represent fenestrations,
although they were slightly larger than the 60–80 nm
estimated from ex vivo studies.3,4.These were greatly increased
in number by VEGF (Figure 2).
Gene expression analysis by cDNA array
mRNA analysis demonstrated that the overall expression
patterns of genes represented on the array used were very
similar for primary and ciGEnC at both permissive and
non-permissive temperatures, but quite different from the
expression pattern for the podocytes used as a control
(Figure 3). The analysis confirmed the expression of the EnC-
specific markers PECAM1, intercellular adhesion molecule 2
(ICAM2, CD102), VEGFR2, and vWF in the three GEnC
groups, but not in podocytes (Table 1). There were some
differences between the three GEnC groups in levels of
mRNA expression in these experiments, for example,
relatively higher expression of VEGFR2 and vWF in ciGEnC.
Interestingly, some genes involved in extracellular matrix
production and regulation (plasminogen activator inhibitor-
1, thrombospondin, fibronectin) were highly expressed in all
GEnC and podocytes (Table 1).
Immunofluorescence of ciGEnC monolayers and cell-based
fluorescence immunoassay
CiGEnC expressed the EnC-specific markers PECAM1, vWF,
and VE-cadherin comparable in distribution and level of
expression to primary culture GEnC (Figure 4). Podocytes
were, as expected, negative for these markers. Treatment of
ciGEnC with TNFa caused a dose-dependent increase in
expression of E-selectin by cell-based fluorescence immu-
noassay (Figure 5), but had no effect on binding of an
irrelevant primary antibody (not shown). TNFa (10 ng/ml)
caused a 3.2-fold increase in E-selectin expression over 6 h.
Western blotting
Western blotting confirmed that ciGEnC retain the expres-
sion of the important EnC-specific molecules PECAM1,
ICAM2, VEGFR2, vWF, VE-cadherin, and Tie2 at both 331C
and 371C (Figure 6). These results correspond to and confirm
similar gene array results for PECAM1, ICAM2, VEGFR2,
and vWF. There were comparable levels of expression in
primary and ciGEnC, although as above there appeared to be
greater expression of VEGFR2 and vWF in ciGEnC.
Western blotting also confirmed expression of the SV40LT
antigen in ciGEnC at 331C and its silencing by transfer of
cells to 371C. Time-course analysis showed SV40LT levels
rapidly reducing within 24 h with a greater than 30-fold
reduction 5 days after transfer than at 331C (Figure 7). Cells
were taken to be quiescent by day 5 and were used in
experiments after that time point.
Trans-endothelial electrical resistance and effects of
thrombin and cAMP
CiGEnC monolayers at 331C reached a mean trans-
endothelial electrical resistance (TEER) of 20–25O at 6 days
post-seeding, after which the TEER plateaued (data not
shown). Monolayers transferred to 371C on day 6 maintained
a similar TEER for a further 7 days. Increasing the effective
Control VEGF
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Figure 2 | SEM showing the presence of fenestrations 50–400 nm
in diameter (arrows) in ciGEnC at 371C under usual conditions
(control) and the striking increase in their number after 24 h
treatment with 100 ng/ml VEGF. Bar¼ 1 mm.
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Figure 3 | Focused gene array images derived from mRNA
extracted from primary culture GEnC, ciGEnC at 331C, and after 7
days at 371C and podocytes (control). Pattern of expressed mRNA
detected is similar for all three GEnC types, but quite different for
podocytes. Examples of groups of four quadruplicate dots repre-
senting endothelial cell-specific markers are indicated by numbered
circles; 1: ICAM2, 2: VEGFR2, 3: PECAM1, 4: vWF. One of the control
genes, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), is also
indicated.5
Table 1 | Relative expression of endothelium-specific and
matrix-related genes in GEnC, selected from genes analysed
by focused gene array
Gene expression level (ratio of gene:GAPDH dot
density) for different cell types
Gene
Primary
GEnC
CiGEnC
331C
CiGEnC
371C Podocytes
Endothelium-specific
PECAM1 1.12 0.93 0.98 0.08
ICAM2 1.04 1.08 1.26 0.02
VEGFR2 0.27 0.75 0.81 0.01
vWF 0.17 0.48 0.66 0.05
Matrix-related
PAI-1 1.15 1.08 1.15 1.04
Thrombospondin 1.05 1.11 1.13 1.08
Fibronectin 1.15 1.05 1.22 1.07
ciGENC, conditionally immortalized glomerular endothelial cells; ICAM, intercellular
adhesion molecule; PAI, plasminogen activator inhibitor; PECAM, platelet endothe-
lial cell adhesion molecule; VEGFR, vascular endothelial growth factor receptor; vWF,
von Willebrand factor.
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intracellular concentration of cAMP by use of the ‘cAMP
medium’ increased the mean TEER of ciGEnC monolayers at
371C by 6.3O, while thrombin decreased TEER by 7.6O over
1 h relative to controls (Figure 8).
DISCUSSION
We have described for the first time the generation of
immortalized human GEnC. Significantly, this immortaliza-
tion is conditional by use of a temperature-sensitive
transgene encoding SV40LT. This allows both an unlimited
replication potential and return of cells to a non-proliferative
state by transfer to the non-permissive temperature of 371C.
Western blotting confirmed rapid reduction of SV40LT levels
after transfer to 371C. This is consistent with previous
observations on other cells, ci in a similar way, which show
rapid SV40LT loss on transfer to the non-permissive
temperature, leading to growth arrest, while metabolic
activity is maintained.30 Indeed the tsA58 mutant was
selected as the source of SV40LT for this property of rapid
degradation at the non-permissive temperature.30 In addi-
tion, we have also incorporated a transgene encoding hTERT,
shown to be essential for successful immortalization of
human EnC in previous studies.28
We have directly compared ciGEnC with primary culture
human GEnC, previously characterized in detail,24 and
shown that they retain similar morphological appearances
at both non-permissive and permissive temperatures. Similar
PECAM1
VE-cadherin
vWF
GEnC (primary) ciGEnC 33°C ciGEnC 37°C Podocyte
Figure 4 | Immunofluorescence microscopy showing expression of EnC-specific markers PECAM-1, VE-cadherin, and vWF by primary
culture GEnC, ciGEnC at 331C, and after 14 days at 371C. Podocytes used as a control are negative for these EnC markers as expected.
Original magnification  1000.
0
0 0.1 1 10
200
400
600
800
1000
Fl
uo
re
sc
en
ce
 e
m
is
si
on
(a.
u.)
TNF concentration (ng/ml)
Figure 5 | Chart showing the effect of TNFa on e-selectin
expression by ciGEnC in a cell-based FIA. CiGEnC at 371C were
incubated with TNFa at various concentrations or control medium for
6 h before fixing and labelling for E-selectin. E-selectin expression is
proportional to fluorescence emission. Bars show mean7s.e., n¼ 15,
Po0.0001 by analysis of variance.
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Figure 6 | Western blotting analyses of protein extracted from
glomeruli sieved from normal renal cortex (Glom), ci podocytes
(Pod) at 331C, primary culture GEnC and ciGEnC at 331C, and
after 10 days at 371C, demonstrating the expression of EnC-
specific markers in all GEnC lanes and of SV40LT in ci podocytes
and ciGEnC at 331C. Images were derived from identical gels, with
each lane loaded with the same amount (10 mg) of the same protein
samples. Actin bands confirm the loading of comparable amounts of
protein. Numbers indicate the expected molecular weight of bands
and correspond to molecular weights of marker proteins (not shown).
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patterns of mRNA expression were seen using a focused gene
array including the expression of EnC-specific markers
PECAM1, ICAM2, VEGFR2, and vWF. The expression of
these markers was validated at the protein level by Western
blotting and/or immunofluorescence. GEnC were also shown
to express VE-cadherin and Tie2 at comparable levels in
primary and ci cells by Western blotting. Further interesting
data from the gene array experiments show that GEnC, like
podocytes in culture, expressed high levels of mRNA for
proteins which are extracellular matrix components (fibro-
nectin, thrombospondin) or involved in regulation of
biological reactions occurring in it (plasminogen activator
inhibitor-1). This may be important in the production and
remodelling of the glomerular basement membrane in vivo.
CiGEnC retained EnC behaviours which are important
in vivo, and hence will be important in their further use for
in vitro studies. Like primary culture GEnC, ciGEnC
upregulated E-selectin in response to the inflammatory
mediator TNFa and they formed restrictive monolayers in
culture. These monolayers were responsive to both cAMP
and thrombin as we have previously shown for primary
culture GEnC, and comparable to EnC of other types.24
For the first time in cultured GEnC we have shown the
upregulation of fenestrations in response to VEGF. The
presence of fenestrations in vivo is essential for the high
hydraulic conductivity of the glomerular filtration barrier
and hence glomerular filtration. The fact that similar
structures are expressed in vitro suggests that observations
on the barrier-forming properties of these cells will be
relevant to pathophysiology of the intact glomerulus.
Expression of VEGF receptors and responsiveness to this
mediator are particularly noteworthy in this respect as
evidence suggests the importance of VEGF in normal
glomerular physiology in maintenance of the endothelium
as well as in glomerular disease.31 It has long been suggested
that VEGF, produced by podocytes, may induce GEnC
fenestrations.5,32 Although it is yet to be proven that this
occurs in vivo, these in vitro observations lend further weight
to this hypothesis and are consistent with our previous
observations of VEGF reducing the TEER of primary culture
GEnC monolayers.24
The ready availability of large numbers of human GEnC
now opens the door for detailed in vitro studies. Formation
of restrictive monolayers indicates that these cells will be
useful for further investigation of GEnC barrier function,
including analysis of the role of glycocalyx. This will enable
greater understanding of the contribution of GEnC to
physiological glomerular permselectivity and to disturbances
in disease states. This includes intrinsic glomerular diseases
where the exact mechanisms of proteinuria are yet to be
elucidated, and also those systemic conditions in which there
is a more modest increase in glomerular permeability
resulting in microalbuminuria. Study of GEnC in culture
may illuminate the important conundrum of why micro-
albuminuria is a powerful independent risk factor for disease
in other vessels and hence for cardiovascular disease.33
Increasing evidence indicates the importance of interactions
between GEnC and podocytes in filtration barrier function in
health and disease.24 As we have previously derived ci
podocytes, we can now study the two cell types separately
and together in further in vitro analyses of factors involved in
glomerular permeability.
In summary, we have successfully addressed the problem of
poor replicative potential of human GEnC in vitro by
development of ciGEnC, which represent a unique resource
for further study. The importance of studying the relevant cell
type in tissue culture studies is clear and hence these cells
significantly advance our ability to understand the human
renal glomerulus through in vitro investigations. The cells
retain the characteristics of primary culture cells, including
aspects of their highly specialized in vivo ultrastructure such as
fenestration formation. These cells have been developed at
a time of rapidly increasing understanding of the ultrastruc-
tural and molecular basis of glomerular permselectivity in
health and disease through the detailed study of podocytes.34
In the light of observations indicating that the glomerular
endothelium also plays a vital role, a complementary study of
these ciGEnC promises to further enhance this progress.
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Figure 7 | Western blotting analyses (top panel) and ratio of band
density of SV40LT to actin (lower panel) of protein extracted
from ciGEnC at 331C (day 0) and at 371C (day 1–5), demonstrating
the rapid loss of expression of SV40LT on transfer to the non-
permissive temperature. Images were derived from identical gels
with each lane loaded with the same amount (10 mg) of the same
protein samples. Actin bands confirm the loading of comparable
amounts of protein. Numbers indicate the expected molecular
weight of bands and correspond to molecular weights of marker
proteins (not shown).
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Figure 8 | Chart showing the results of separate experiments
examining the effect of cAMP medium (containing 2 lM RO-20-
1724 and 30 lM 8-(4-chlorophenylthio)-cAMP) or thrombin (1 U/
ml) on TEER of ciGEnC monolayers after 1 h. Bars show mean7s.e.,
n¼ 3, Po0.05 for effect of each mediator, P-values by t-test. cAMP
medium increased TEER by 6.3O, while thrombin decreased TEER by
7.6O relative to control.
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MATERIALS AND METHODS
Cell culture
Primary culture GEnC derived from isolated human glomeruli were
prepared as described previously.7 Additional primary culture GEnC
derived from glomeruli isolated from normal human kidney and
decapsulated by sieving (according to the supplier’s data sheet) were
obtained at passage 2 from the Applied Cell Biology Research
Institute (ACBRI, Kirkland, WA, USA) as previously characterized
in detail.24 Cells were cultured in endothelial growth medium 2 –
microvascular (EGM2-MV, Cambrex, Wokingham, UK) containing
foetal calf serum (5%) and growth factors as supplied, excepting
VEGF unless otherwise stated. Human ci podocytes were cultured in
RPMI 1640-based medium as described previously.19 A mouse
fibroblast cell line (NIH 3T3, obtained from the European
Collection of Cell Cultures via Sigma Chemical Co., St Louis, MO,
USA) was cultured in the same RPMI-based medium.
Ci – retroviral construct, generation of amphotropic viruses,
and virus infection
Two packaging cell clones producing helper-free amphotropic
murine-leukemia-virus particles as described previously were
used.28 Briefly, the first, based on the packaging cell line PA317,
produced viral particles containing an SV40LT antigen gene
containing both tsA58 and the U19 mutations. The second, based
on the packaging cell line TEFLY-A, produced virus particles
containing hTERT. Cultures of primary human GEnC (at passage
4–6) were simultaneously infected with retrovirus-containing super-
natants from the two packaging cell lines. Midconfluence proliferat-
ing cultures were exposed to freshly thawed filtered (0.45 mm)
supernatant mixed 1:1 with growth medium plus 8 mg/ml polybrene
for 18 h before being replaced with usual growth medium. The cells
were allowed to reach confluence at 371C. Cells transduced with the
SV40LT construct were selected with 0.5 mg/ml G418 (Life
Technologies BRL, Paisley, UK) and cells were placed at 331C. Cells
were maintained at this temperature for the remainder of the
procedure. At 5 days the medium was changed for normal growth
medium. After 2 weeks clones of healthy cells selected for the
SV40LT construct began to appear. Some of these patches were
removed from the flask using cloning rings and transferred to fresh
flasks. After reaching confluence, cells also transduced with hTERT
were selected with 25mg/ml hygromycin (Sigma) for 5 days, after
which surviving cells were allowed to approach confluence in
standard medium.
Subcloning of cell lines
Flasks of cells were selected by phase-contrast microscopy for
dilution cloning and further characterization on the basis of the
greatest similarity with primary culture cells, homogeneity, and
continued proliferation at 331C. Fibroblasts, to be used as feeder
cells, were treated with mitomycin-C (0.25 mg/ml, Sigma) for 12 h to
render them non-proliferative. After washing in usual growth
medium, and a further 48 h in culture, fibroblasts were plated at
10 000 cells/cm2, resulting in a 70% confluent cell layer. After
another 24–48 h, GEnC were seeded into the same plates at
concentrations of 10 or 50 cells/ml. Single-cell clones were selected
at 21–28 days using cloning rings and were transferred to fresh
culture plates.
Propagation of cells
Cells were grown to confluence at 331C, trypsinized, and reseeded in
fresh flasks at a dilution between 1:3 and 1:5. Cells were grown to
confluence before thermoswitching to 371C. This was chosen as the
non-permissive temperature, as in previous studies EnC containing
the tsA58 SV40LT mutant were fully arrested at this temperature,
although the full non-permissive temperature for tsA58 is 39.51C.28
Phase-contrast microscopy
CiGEnC at various passages were seeded in flasks at subconfluent
density, placed at either 331C or 371C, and morphology was
examined by phase-contrast microscopy over time. Appearances
were compared with primary culture cells and digital images were
acquired.
Scanning electron microscopy
Cells grown to confluence on plastic (Thermanox, Nalge Nunc
International, Rochester, NY, USA) coverslips were fixed in 2.5%
glutaraldehyde in 0.1 M Sorenson’s phosphate buffer, fully dehy-
drated in graded ethanol, critical point dried, and sputter coated
with gold. Specimens were examined in a JEOL 840A scanning
electron microscope (JEOL, Tokyo, Japan) at 10 kV. In some cases
cells were exposed to VEGF (100 ng/ml, R&D Systems, Minneapolis,
MN, USA) for 24 h prior to fixation.
Gene expression analysis by focused array
Messenger RNA was extracted from cultured GEnC, and human
podocytes used as a control, using an ArrayGrade mRNA
purification kit (SuperArray Inc., Bethesda, MD, USA). Gene
expression was analysed using a human endothelial cell biology
gene array kit (GEArray Q-series, HS-036, SuperArray Inc.). Each
array was a 3.8 4.8 cm nylon membrane spotted with cDNA
fragments of 96 marker genes in quadruplicate. These included four
positive controls including glyceraldehyde-3-phosphate dehydro-
genase, a negative control, and a range of endothelium-related
genes. Briefly, 0.5 mg mRNA was used as template for biotinylated
cDNA probe synthesis. RNA was reverse-transcribed using gene-
specific primers and cDNA was amplified and labelled with biotin-
16-deoxyuridine triphosphate using an AmpoLabelling-LPR Kit
(SuperArray Inc.). Biotinylated cDNA probes were denatured and
hybridized to the array membranes, which were then washed,
blocked, and incubated with alkaline phosphatase-conjugated
streptavidin. The hybridized biotinylated probes were detected by
a chemiluminescent method using the alkaline phosphatase
substrate, CDP-Star. The results were analysed using ScanAlyze
software (Stanford University, Stanford, CA, USA). Expression levels
of individual genes in each mRNA extract were expressed as a ratio
of the overall density of the quadruplicate spots representing each
gene versus the density of the quadruplicate spots representing
glyceraldehyde-3-phosphate dehydrogenase, after background cor-
rection. The gene array data on selected endothelial-specific markers
were validated by immunofluorescence and Western blotting.
Immunofluorescence
Cells grown to confluence on collagen (Autogen Bioclear, Calne,
Wilts., UK)-coated glass coverslips were fixed in 2% formaldehyde
and permeabilized in 0.3% Triton X-100. Cells were incubated with
blocking solution (5% foetal calf serum and 0.05% Tween 20) and
then with antibodies to PECAM1 (R&D Systems), VE-cadherin
(Santa Cruz Biochemicals, Santa Cruz, CA, USA), vWF (Dako-
Cytomation, Ely, Cams, UK), and SV40LT (Pharmingen, San Diego,
CA, USA). Primary antibody binding was detected using fluorescein
isothiocyanate-conjugated secondary antibodies (Jackson Immuno
Research Laboratories Inc, West Grove, PA, USA). Podocytes were
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used as controls. Coverslips were mounted in Vectashield aqueous
mountant (Vector Laboratories, Peterborough, UK) and examined
using a Leica DMRB fluorescence microscope (Leica, Solms,
Germany).
Cell-based fluorescence immunoassay
A fluorescence immunoassay, as described previously,24 was used to
quantify changes in E-selectin expression in response to TNFa.
CiGEnC at 331C were seeded in 96-well plates at 10 000 cells/well.
After 5 days cells were transferred to 371C and after a further 7 days
were treated with TNFa (0–10 ng/ml, R&D Systems) for 6 h. The
cells were fixed and permeabilized as above, then incubated with an
antibody to E-selectin (R&D Systems), which was detected with a
fluorescein isothiocyanate-labelled secondary antibody as above. An
irrelevant primary antibody was used as a control. Fluorescence
emission at 520 nm after excitation at 490 nm was measured on
a Packard Instruments FluoroCount fluorospectrophotometer
(Perkin-Elmer Life Sciences, Boston, MA, USA).
Western blotting
CiGEnC at 331C or after 10 days at 371C were lysed in Laemmli
sample buffer and solubilized protein concentrations were deter-
mined (bicinchoninic acid assay; Pierce Chemical Co., Rockford, IL,
USA). Lysates of primary culture GEnC, podocytes and sieved
glomeruli (as described previously32) were used as controls. Protein
samples were separated by electrophoresis under reducing condi-
tions and were blotted onto nitrocellulose membranes. The
membranes were immunolabelled with antibodies to vWF, VE-
cadherin, SV40LT (as above), Tie2, VEGFR2 (both Santa Cruz),
ICAM2 (R&D Systems), and actin (Sigma). Bands were detected by
enhanced chemiluminescence (Amersham Biotech Ltd., Bucks.,
UK). In other experiments, ciGEnC were lysed at successive time
points and SV40LT expression analysed as above.
Measurement of TEER
TEER is a measure of ion flux and is inversely related to the
fractional area of pathways open to water and small molecules across
a cell monolayer. Tissue culture inserts containing polycarbonate
supports (0.4 mm pore size, Nalge Nunc International, Rochester,
NY, USA) were seeded with ciGEnC at 100 000 cells/cm2. Measure-
ment of TEER of GEnC monolayers was performed as described
previously using an Endohm 12 electrode chamber and EVOMx
voltometer (World Precision Instruments, Sarasota, FL, USA).24
TEER was measured sequentially in ciGEnC monolayers at 331C.
Some inserts were transferred to 371C on day 6 after seeding with
continued monitoring of TEER.
Effects of cAMP and thrombin on ciGEnC monolayers
The effects of a cAMP analogue and thrombin were examined as
increasing intracellular cAMP decreases permeability in primary
culture GEnC and other EnC, while thrombin has opposite
effects.24,35 Cell membranes are impermeable to cAMP, so a cell
membrane-permeable cAMP analogue, 8-(4-chlorophenylthio)-
cAMP (Sigma), was used in combination with a cAMP-specific
phosphodiesterase inhibitor, RO-20-1724 (CN Biosciences, Notting-
ham, UK). Inserts containing ciGEnC monolayers maintained at
371C for 7 days were used. Culture medium in both wells and inserts
was replaced with serum-free medium. Baseline TEER was measured
after 1 h and the culture medium was again replaced, this time with
serum-free medium containing 20 mM RO-20-1724 and 300mM 8-(4-
chlorophenylthio)-cAMP (‘cAMP medium’) or 1 U/ml thrombin
(Sigma) or with medium alone (control). TEER was remeasured
after 1 h.
Statistics
Microsoft Excel software (Microsoft Corporation, Washington, DC,
USA) was used for simple statistics. SPSS 11.0 (SPSS, Chicago, IL,
USA) was used for other tests, including standard error (s.e.).
P-values of o0.05 were taken to indicate the statistical significance.
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